First heart pacemaker able to recruit stem cells to damaged heart tissue – THE MYOSTIM PACER – will be introduced
LOS ANGELES, May 1, 2013 /PRNewswire/ — Heart Rhythm 2013 will be held in Denver, Colorado May 8th to 11th – http://www.hrsonline.org/. Leonhardt Ventures and MyoStim Pacers are co-sponsoring @ 3pm on May 9th at their exhibit booth No. 657 a showcase of technologies that address heart and cardiovascular disease.
Companies to be showcased include:
MyoStim Pacers – http:/www.myostimpacers.com – world's first heart failure pacemaker with ability to recruit reparative stem cells to damaged and weakened heart tissue.
Bioheart, Inc. – http://www.bioheartinc.com – Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.
BioPace – world's first biological pacemaker made entirely of living cells.
CoroStim – world's first vibrational energy emitting pacemaker that prevents plaque formation in high risk coronary arteries.
BioLeonhardt – http://www.bioleonhardt.com – combination electrical stimulation and multi-stage cell and gene therapy method, composition and devices for treating advanced heart failure. Featuring combined utilization of MicroRNAs, nutrient time release SDF-1, hydrogel, cardiac stem cells, iPS cells and muscle progenitor stem cells. First method under testing with up to 36 repeat injection sessions of stem cells over time via a needle catheter.
Cardiobridge – http://www.cardiobridge.com – Highest flow rate 10FR circulatory support catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI. Data on about 30 clinical patients will be presented.
AortaCell – Method and device to treat aortic aneurysms non-invasively with an abdominal belt that delivers focal wireless electrical energy to weakened aortic wall that causes reparative autologous stem cells to home to that chosen treatment location.
EndoCell – Method and device for growing new endothelium lining of a damaged artery with a percutaneous needle catheter and endothelial progenitor cells.
MyoValve – Cell seeding method and device for heart valve leaflets invivo or invitro. Designed to reduce risk of calcification and valve replacement.
Valvublator – Percutaneous catheter device for de-calcifying heart valves so a patient may keep their own valve instead of getting an artificial implant.
HeartScore – Composite scoring system of genetic, blood and scan test results (some point of care) that are loaded into the SecondBeat wearable wrist watch for a baseline score. The watch has an infrared sensor that measures real time endothelial health. The baseline score goes up or down if the patient eats well, exercises well and is compliance with all doctor prescribed medicines and protocols. The composite HeartScore is clearly viewable to patients to help real time guidance of their heart and cardiovascular health.
About Leonhardt Ventures: Since 1983 Leonhardt Ventures www.leonhardtventures.com has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 200,000 patients have been treated to date with Leonhardt inventions. In the 1980's the group developed market leadership in patented polyurethane balloon catheters including drug, stem cell and radiation delivery systems. In the 1990s they developed over 20 additional devices including the first commercially successful stent graft for aortic aneurysm repair (TALENT – Taheri-Leonhardt Stent Graft). The team completed the first ever truly percutaneous repair of an aortic aneurysm without surgery in Melbourne, Australia in 1995. Published the first thoracic aortic dissection repair with stent grafts paper in The New England Journal of Medicine in 1999. The first conformance sealing stent graft. The first above renal fixation stent graft. The first customized to fit individual patient stent grafts. The first multi-stage low profile stent graft. The first removable stent graft. The first foam and bioglue sealing cuff for stent grafts. The first use of muscle stem cells to reinforce aortic wall necks after stent graft placement. The team developed and patented the first percutaneous heart valve, intravascular lung catheter, the Pro-Cell intracavity stem cell delivery system and the MyoCath line of stem cell delivery catheters. Leonhardt patented inventions include the first heart pacemaker able to recruit reparative stem cells to damaged heart tissue (MyoStim Pacers). In 2001 the team led the first in the world non-surgical case of stem cell repair of damaged heart muscle in a human patient with Bioheart MyoCell. That led to the first Phase III double blinded, randomized, placebo controlled trial for stem cells growing new contractile muscle in post heart attack tissue in advanced heart failure patients – results published in the American Heart Journal Bioheart MyoCell pts 95.7 meters improvement in exercise capacity over placebo (minus 4 meters decline). The team is preparing to complete the first ever biological pacemaker implantation in a human patient within the next 12 months (BioPace). Bioheart committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.
Contact: Howard Leonhardt, Leonhardt Ventures, 1531 6th Street, Unit 401, Santa Monica, California, 90401, 310 310 2534, email: Email